Gilead’s DAR-311 (DORADO) Phase III trial evaluating its once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, achieved positive results. DAR-311 is an international Phase III double-blind, placebo-controlled parallel group trial, in which 379 patients were randomized to receive once-daily doses of darusentan 50 or placebo for up to 14 weeks as an add-on to existing antihypertensive regimens. The co-primary efficacy endpoints wer...